Contact


Mailing Address

Donate

Your tax deductible gift in any amount helps support our efforts to advocate for more research, better treatments, and ultimately, a cure for IH.

Donate
 

Author:hfadmin

Arise Clinical Trial

CLINICAL TRIAL ENROLLING PATIENTS WITH IDIOPATHIC HYPERSOMNIA AND NARCOLEPSY TYPE 2 Balance Therapeutics is evaluating an investigational new drug BTD-001, to treat excessive daytime sleepiness in individuals diagnosed with idiopathic hypersomnia (IH) or narcolepsy type 2 (Na-2). A Phase 2 clinical trial is currently enrolling Na-2 subjects at 26...

Continue Reading

Get “Somnusnooze”, our monthly e-newsletter

Sign up to receive HF updates, news from the world of sleep research, first-person stories, and more.

You will receive an email from info@hypersomniafoundation.org (please check your junk/spam folder if needed) to confirm your subscription to our newsletter through MailChimp. You are not subscribed until you confirm. We recommend that you add info@hypersomniafoundation.org to your contacts and/or safe email list (whitelist) to ensure you receive all future newsletters. Thank you for your interest in the Hypersomnia Foundation!